OncoMatch/Clinical Trials/NCT05683808
Venous Thromboembolism Prevention in Outpatients With Glioma
Is NCT05683808 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Apixaban for glioblastoma.
Treatment: Apixaban — This is an open label study of apixaban for venous thromboembolism prevention in patients with newly diagnosed grade 4 glioma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Disease stage
Required: Stage WHO GRADE 4 (WHO)
Grade: 4 (WHO)
malignant glioma, World Health Organization (WHO) grade 4
Performance status
KARNOFSKY 60–100
Lab requirements
Blood counts
platelets of greater than or equal to 100,000
Kidney function
glomerular filtration rate (GFR) greater than or equal to 25
Acceptable labs, including platelets of greater than or equal to 100,000, glomerular filtration rate (GFR) greater than or equal to 25.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Vermont Medical Center · Burlington, Vermont
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify